Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANG1007
- Development stage
- Preclinical
- Lead developer
- Angiochem
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
ANG1007 is a preclinical peptide-drug conjugate (PDC) developed by Angiochem for the treatment of brain cancer. It utilizes Angiochem's proprietary **Angiopep** technology, specifically the **Angiopep-2** peptide, which is designed to cross the blood-brain barrier (BBB) by targeting the low-density lipoprotein receptor-related protein 1 (LRP1) via receptor-mediated transcytosis. In ANG1007, Angiopep-2 is conjugated to the cytotoxic anthracycline **doxorubicin**. By leveraging this transport mechanism, the drug aims to deliver doxorubicin directly into the central nervous system, bypassing the BBB which typically excludes doxorubicin from the brain. Once delivered to tumor cells, doxorubicin exerts its antineoplastic effect through DNA intercalation and the inhibition of topoisomerase II, leading to DNA damage and apoptosis.
- Other names
- Angiopep-2-doxorubicin conjugateAngiopep2-doxorubicin conjugateAngiopep 2-doxorubicin conjugate
02
Targets
DNATOP2A (DNA topoisomerase II)LRP1 (Prolow-density lipoprotein receptor-related protein 1)
Beyond the preview
Go deeper on ANG1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANG1007.